KLRA (Kailera Therapeutics) Change In Receivables: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
12 GF Score
Price $12.83
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Change In Receivables?

Kailera Therapeutics KLRA -0.54% 12 Change In Receivables is $ Mil as of Jun. 2026. GuruFocus rates KLRA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Kailera Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $ Mil. It means Kailera Therapeutics's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Kailera Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $ Mil. It means Kailera Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Kailera Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $ Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kailera Therapeutics's liquidation value for the three months ended in Jun. 2026 was $823.79 Mil.

Kailera Therapeutics  (NAS:KLRA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kailera Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=/0*91
=

2. In Ben Graham's calculation of liquidation value, Kailera Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Kailera Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=916.741-92.952+0.75 * +0.5 * 0
=823.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Change In Receivables Related Terms

Kailera Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Change In Receivables Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Change In Receivables
- -

Kailera Therapeutics Quarterly Data
Jun25 Mar26 Jun26
Change In Receivables - - -
KLRA
12GF Score
Kailera Therapeutics Inc KLRA
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $ Mil mean?
Kailera Therapeutics (KLRA) has a Change In Receivables of $ Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Change In Receivables too high?
Kailera Therapeutics' current Change In Receivables is $ Mil. Overall, Kailera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Change In Receivables compare to VCEL and ADMA?
Kailera Therapeutics' Change In Receivables of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Kailera Therapeutics and its competitors. Kailera Therapeutics's current Change In Receivables is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Change In Receivables of $ Mil. The current Change In Receivables is $ Mil. Kailera Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Change In Receivables is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
12GF Score

Get the complete analysis for KLRA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.83
Price